“The global NGS market is expected to reach USD 10,371.1 million by 2021 from USD 4,031.7 million in 2016, at a CAGR of 20.8% between 2016 and 2021. North America is expected to hold the largest share of the global NGS market in 2016. The NGS market is broadly segmented into products & services, technology, application, and end user. By products & services, the NGS market is segmented into pre-sequencing products & services, NGS platforms, consumables, sequencing services, data analysis/bioinformatics. The consumables segment is expected to command the major share of the NGS market, by products& services, in 2016.
Geographically, the report covers four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to command the largest share of the global NGS market in 2016, followed by Europe. Asia-Pacific NGS market is poised to witness highest growth rate during the forecast period from 2016 to 2021 due to a number of factors including improving healthcare infrastructure and favorable government initiatives.
Market growth is majorly driven by the technological advancements in NGS products, increasing applications of NGS, entry of new market players, increasing partnerships & collaborations among market players, and growing incidences of cancer, inherited rare disorders, and pre- and neo-natal disorders.
As of 2015, the global NGS market was dominated by Illumina, Inc. (U.S.); Thermo Fisher Scientific, Inc. (U.S.); and Pacific Biosciences of California, Inc. (U.S.) which together held a share of 94% of the overall NGS platforms market. New product launches & product enhancements; agreements, collaborations, & partnerships, geographic expansions; strategic acquisitions; and others (offering research fund & grants and organizing conferences/seminars) are the major strategies adopted by most market players to achieve growth in the global NGS market.
Reasons to Buy the Report:
From an insight...